Fetal growth restriction
Using pre-clinical models of fetal growth restriction (FGR), the group has sought to better understand fetal adaptations to impaired placentation and thereby develop better diagnostics and therapies. Dr Suzie Miller, head of the Neurodevelopment and Neuroprotection group, is driving much of the fundamental (experimental) work in this area. Insights gained from the experimental studies have informed the design of clinical trials of melatonin as a neuro- and cardio-protectant, reducing the risks of brain injury and cardiovascular impairment. Follow-up studies of the children are being led by Professor Rosemary Horne and Associate Professor Michael Fahey. A world first trial was recently completed using melatonin in pregnant women to prevent cerebral palsy.
Professor Rosemary Horne – NHMRC Senior Research Fellow, Department of Paediatrics
Associate Professor Michael Fahey – Paedatric Neurologist, Department of Paediatrics
Dr Stephanie Yiallourou – Senior Postdoctoral Research Fellow, Department of Paediatrics